Major Depressive Disorder. Major depressive disorder, single episode
Conditions
Interventions
Intervention 1: Intervention group: Bupropion (Welban company) with the starter dose of 75 mg/day and maximum dose of 300 mg daily for at least 4 weeks. Intervention 2: Control group: Citalopram Pharm
Sponsors
Gorgan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to No maximum
Inclusion criteria
Inclusion criteria: Diagnosis of major depressive disorder based on structured clinical interview and DSM-5 Older than 30 years old Sufficient fluency in Farsi and literacy reading and writing lack of any comorbid disorder, especially anxiety disorders and substance use retarded or normal psychomotor
Exclusion criteria
Exclusion criteria: previous appropriate response to a certain antidepressants taking antidepressants when visiting using BZDs, mood stablizers or antipsychotics concurrent psychotherapy medical conditions including cardiovascular disease suicidal ideations and psychotic symptoms need to admit to the mental ward agitation or mixed mood symptoms
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective treatment response. Timepoint: at baseline and 2 and 4 weeks after pharmacotherapy. Method of measurement: Reduction of more than 50% of base score on Hamilton Depression Rating Scale (HAM-D).;Subjective treatment response. Timepoint: at baseline and after 2 and 4 weeks of pharmacotherapy. Method of measurement: reduction of baseline score in Cognitive Triad Inventory (TCI). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Mitra Joodi Mashhad
Gorgan University of Medical Sciences
Outcome results
None listed